de Groot RJ, Baker SC, Baric R, Enjuanes L, Gorbalenya AE, Holmes KV, Perlman S, Poon L, Rottier PJ, Talbot PJ, Woo PC, Ziebuhr J. Family Coronaviridae. In: King AM, Lefkowitz E, Adams MJ, Carstens EB, editors. Ninth Report of the International Committee on Taxonomy of Viruses. Oxford: El., I. U. of M. S. V. D., International Committee on Taxonomy of Viruses; 2011, p. 806–28.
Google Scholar
ICTV Master Species List 2009—v10, International Committee on Taxonomy of Viruses.
Gorbalenya AE, Enjuanes L, Ziebuhr J, Snijder EJ. Nidovirales: evolving the largest RNA virus genome. Virus Res. 2006;117(1):17–37.
CAS
PubMed
PubMed Central
Google Scholar
NHS, SARS (severe acute respiratory syndrome). [Online]. https://www.nhs.uk/conditions/sars/. Accessed 15 Feb 2020.
WHO. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. 2003. [Online]. https://www.who.int/csr/sars/country/table2004_04_21/en/. Accessed 15 Feb 2020.
CDC. MERS Clinical Features, Middle East Respiratory Syndrome (MERS). 2019. [Online]. https://www.cdc.gov/coronavirus/mers/clinical-features.html. Accessed 15 Feb 2020.
WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). 2020. [Online]. https://www.who.int/emergencies/mers-cov/en/. Accessed 3 Apr 2020.
WHO. Middle East respiratory syndrome coronavirus (MERS-CoV)—Republic of Korea. 2015. [Online]. https://www.who.int/csr/don/25-october-2015-mers-korea/en/. Accessed 15 Feb 2020.
Hui DS, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health; the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264–6.
CAS
PubMed
PubMed Central
Google Scholar
WHO. WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020. 2020. [Online]. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Accessed 15 Mar 2020.
WHO. Coronavirus disease 2019 (COVID-19): situation report, 74. 2020. [Online]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed 3 Apr 2020.
WHO. Q&A on coronavirus (COVID-19). 2020. [Online]. https://www.who.int/news-room/q-a-detail/q-a-coronaviruses. Accessed 3 Apr 2020.
Mak TW, Saunders ME. Chapter 14—Vaccination. In: Jett E, editor. B D. B. T.-P. to the I. R. Primer to the immune response. 2nd ed. Boston: Academic Cell; 2014. p. 333–75.
Google Scholar
Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226–36.
CAS
PubMed
PubMed Central
Google Scholar
Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82(5):488–96.
CAS
PubMed
Google Scholar
Lauer KB, Borrow R, Blanchard TJ. Multivalent and multipathogen viral vector vaccines. Clin Vaccine Immunol. 2017;24(1):e00298–e316.
CAS
PubMed
PubMed Central
Google Scholar
Urakami A, et al. Development of a novel virus-like particle vaccine platform that mimics the immature form of alphavirus. Clin Vaccine Immunol. 2017;24(7):e00090–e117.
CAS
PubMed
PubMed Central
Google Scholar
Lin J-T, et al. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther. 2007;12(7):1107–13.
CAS
PubMed
Google Scholar
Martin JE, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine. 2008;26(50):6338–433.
CAS
PubMed
PubMed Central
Google Scholar
NIH-ClinicalTrials.gov, Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study. 2013. [Online]. https://clinicaltrials.gov/ct2/show/NCT01376765. Accessed 15 Feb 2020.
Orellana C. Phase I SARS vaccine trial in China. Lancet Infect Dis. 2004;4(7):388.
PubMed Central
Google Scholar
Luo F, Liao F-L, Wang H, Tang H-B, Yang Z-Q, Hou W. Evaluation of antibody-dependent enhancement of SARS-CoV infection in rhesus macaques immunized with an inactivated SARS-CoV vaccine. Virol Sin. 2018;33(2):201–4.
PubMed
PubMed Central
Google Scholar
Tseng C-T, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One. 2012;7(4):e35421.
CAS
PubMed
PubMed Central
Google Scholar
Takasuka N, et al. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol. 2004;16(10):1423–30.
CAS
PubMed
Google Scholar
Tang L, et al. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol. 2004;23(6):391–4.
CAS
PubMed
Google Scholar
Stadler K, et al. SARS vaccine protective in mice. Emerg Infect Dis. 2005;11(8):1312–4.
PubMed
PubMed Central
Google Scholar
Zhou J, et al. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. Vaccine. 2005;23(24):3202–9.
CAS
PubMed
PubMed Central
Google Scholar
Qin E, et al. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine. Vaccine. 2006;24(7):1028–34.
CAS
PubMed
Google Scholar
Bolles M, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 2011;85(23):12201–15.
CAS
PubMed
PubMed Central
Google Scholar
Regla-Nava JA, et al. Severe acute respiratory syndrome coronaviruses with mutations in the E protein are attenuated and promising vaccine candidates. J Virol. 2015;89(7):3870–87.
CAS
PubMed
PubMed Central
Google Scholar
Netland J, et al. Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. Virology. 2010;399(1):120–8.
CAS
PubMed
Google Scholar
Fett C, DeDiego ML, Regla-Nava JA, Enjuanes L, Perlman S. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein. J Virol. 2013;87(12):6551–9.
CAS
PubMed
PubMed Central
Google Scholar
Bukreyev A, et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet (London, England). 2004;363(9427):2122–7.
CAS
Google Scholar
Kapadia SU, Rose JK, Lamirande E, Vogel L, Subbarao K, Roberts A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology. 2005;340(2):174–82.
CAS
PubMed
Google Scholar
Deming D, et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 2006;3(12):e525–e525525.
PubMed
PubMed Central
Google Scholar
DiNapoli JM, et al. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci USA. 2007;104(23):9788–93.
CAS
PubMed
PubMed Central
Google Scholar
Zhao J, et al. Airway memory CD4+ T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity. 2016;44(6):1379–91.
CAS
PubMed
PubMed Central
Google Scholar
Czub M, Weingartl H, Czub S, He R, Cao J. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine. 2005;23(17):2273–9.
CAS
PubMed
PubMed Central
Google Scholar
Bisht H, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA. 2004;101(17):6641–6.
CAS
PubMed
PubMed Central
Google Scholar
Weingartl H, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol. 2004;78(22):12672–6.
CAS
PubMed
PubMed Central
Google Scholar
Chen Z, et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol. 2005;79(5):2678–88.
CAS
PubMed
PubMed Central
Google Scholar
Shim B-S, et al. Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain. Virol J. 2012;9(1):215.
CAS
PubMed
PubMed Central
Google Scholar
See RH, et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol. 2006;87(3):641–50.
CAS
PubMed
Google Scholar
See RH, et al. Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines. J Gen Virol. 2008;89(9):2136–46.
CAS
PubMed
Google Scholar
Yang Z, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 2004;428(6982):561–4.
CAS
PubMed
PubMed Central
Google Scholar
Wang S, et al. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol. 2005;79(3):1906–10.
CAS
PubMed
PubMed Central
Google Scholar
Kam YW, et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine. 2007;25(4):729–40.
CAS
PubMed
Google Scholar
Zhou Z, et al. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine. 2006;24(17):3624–31.
CAS
PubMed
PubMed Central
Google Scholar
Du L, et al. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine. 2007;25(15):2832–8.
CAS
PubMed
Google Scholar
He Y, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun. 2004;324(2):773–81.
CAS
PubMed
PubMed Central
Google Scholar
Zakhartchouk AN, et al. Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine. Vaccine. 2007;25(1):136–43.
CAS
PubMed
Google Scholar
He Y, Li J, Heck S, Lustigman S, Jiang S. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J Virol. 2006;80(12):5757–67.
CAS
PubMed
PubMed Central
Google Scholar
Lokugamage KG, et al. Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. Vaccine. 2008;26(6):797–808.
CAS
PubMed
Google Scholar
Huang J, Cao Y, Du J, Bu X, Ma R, Wu C. Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses. Vaccine. 2007;25(39–40):6981–91.
CAS
PubMed
PubMed Central
Google Scholar
Kong W, et al. Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization. J Virol. 2005;79(22):13915–23.
CAS
PubMed
PubMed Central
Google Scholar
Du L, et al. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine. 2008;26(13):1644–51.
CAS
PubMed
PubMed Central
Google Scholar
Zhao L, et al. Nanoparticle vaccines. Vaccine. 2014;32(3):327–37.
PubMed
Google Scholar
Modjarrad K, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 2019;19(9):1013–22.
CAS
PubMed
PubMed Central
Google Scholar
N. and events University of Oxford. New MERS vaccine clinical trial starts in Saudi Arabia. 2019. [Online]. https://www.ox.ac.uk/news/2019-12-19-new-mers-vaccine-clinical-trial-starts-saudi-arabia. Accessed 15 Feb 2020.
NIH-ClinicalTrial.gov. Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S. 2019. [Online]. https://clinicaltrials.gov/ct2/show/NCT03615911#outcomemeasures. Accessed 15 Feb 2020.
Schindewolf C, Menachery DV. Middle East respiratory syndrome vaccine candidates: cautious optimism. Viruses. 2019;11(1):74.
CAS
PubMed Central
Google Scholar
Xia S, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res. 2014;194:200–10.
CAS
PubMed
PubMed Central
Google Scholar
Almazan F, et al. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. MBio. 2013;4(5):e00650–e713.
PubMed
PubMed Central
Google Scholar
Wirblich C, et al. One-health: a safe, efficient, dual-use vaccine for humans and animals against Middle East respiratory syndrome coronavirus and rabies virus. J Virol. 2017;91(2):e02040–e2116.
CAS
PubMed
PubMed Central
Google Scholar
Deng Y, et al. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerg Microbes Infect. 2018;7(1):60.
PubMed
PubMed Central
Google Scholar
Agrawal AS, et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother. 2016;12(9):2351–6.
PubMed
PubMed Central
Google Scholar
Kim E, et al. Immunogenicity of an adenoviral-based Middle East Respiratory syndrome coronavirus vaccine in BALB/c mice. Vaccine. 2014;32(45):5975–82.
CAS
PubMed
PubMed Central
Google Scholar
Munster VJ, et al. Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. npj Vaccines. 2017;2(1):28.
PubMed
PubMed Central
Google Scholar
Volz A, et al. Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. J Virol. 2015;89(16):8651–6.
CAS
PubMed
PubMed Central
Google Scholar
Malczyk AH, et al. A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform. J Virol. 2015;89(22):11654–67.
CAS
PubMed
PubMed Central
Google Scholar
Haagmans BL, et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science. 2015;351(6268):77–81.
PubMed
Google Scholar
Guo X, et al. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. Immunology. 2015;145(4):476–84.
CAS
PubMed
PubMed Central
Google Scholar
Kato H, et al. Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice. PLoS One. 2019;14(10):e0223684.
CAS
PubMed
PubMed Central
Google Scholar
Alharbi NK, et al. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine. 2017;35(30):3780–8.
CAS
PubMed
PubMed Central
Google Scholar
Alharbi NK, et al. Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels. Sci Rep. 2019;9(1):16292.
PubMed
PubMed Central
Google Scholar
Hashem AM, et al. A highly immunogenic, protective, and safe adenovirus-based vaccine expressing middle east respiratory syndrome coronavirus S1-CD40L fusion protein in a transgenic human dipeptidyl peptidase 4 mouse model. J Infect Dis. 2019;220(10):1558–677.
CAS
PubMed
Google Scholar
Lan J, et al. Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge. EBioMedicine. 2015;2(10):1438–46.
PubMed
PubMed Central
Google Scholar
Wang L, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 2015;6:7712.
CAS
PubMed
Google Scholar
Tai W, et al. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology. 2016;499:375–82.
CAS
PubMed
Google Scholar
Wang Y, et al. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. Hum Vaccin Immunother. 2017;13(7):1615–24.
PubMed
PubMed Central
Google Scholar
Adney RD, et al. Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas. Viruses. 2019;11(3):212.
CAS
PubMed Central
Google Scholar
Zhang Y, et al. Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine. Hum Vaccin Immunother. 2015;11(7):1803–13.
PubMed
PubMed Central
Google Scholar
Ma C, et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine. 2014;32(18):2100–8.
CAS
PubMed
PubMed Central
Google Scholar
Tang J, et al. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum Vaccin Immunother. 2015;11(5):1244–50.
PubMed
PubMed Central
Google Scholar
Nyon MP, et al. Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine. 2018;36(14):1853–62.
CAS
PubMed
PubMed Central
Google Scholar
Zhang N, et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol. 2016;13(2):180–90.
CAS
PubMed
Google Scholar
Lan J, et al. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. PLoS One. 2014;9(11):e112602.
PubMed
PubMed Central
Google Scholar
Coleman CM, et al. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection. Vaccine. 2017;35(12):1586–9.
CAS
PubMed
PubMed Central
Google Scholar
Coleman CM, et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine. 2014;32(26):3169–74.
CAS
PubMed
PubMed Central
Google Scholar
EurekAlert! News Release. MERS-CoV vaccine is safe and induces strong immunity in Army-led first-in-human trial. 2019. [Online]. https://www.eurekalert.org/pub_releases/2019-07/wrai-mvi072319.php. Accessed 15 Feb 2020.
Muthumani K, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med. 2015;7(301):301ra132.
PubMed
PubMed Central
Google Scholar
Chi H, et al. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice. Vaccine. 2017;35(16):2069–75.
CAS
PubMed
PubMed Central
Google Scholar
WHO. DRAFT landscape of COVID-19 candidate vaccines—20 March 2020. 2020. [Online]. https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1. Accessed 15 Mar 2020.
pharmaceutical-technology.com. First US clinical trial of Covid-19 vaccine candidate begins. 2020. [Online]. https://www.pharmaceutical-technology.com/news/first-us-covid-19-vaccine-trial-moderna/. Accessed 10 Apr 2020.
Sutton TC, Subbarao K. Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus. Virology. 2015;479–480:247–58.
PubMed
Google Scholar
Zhao J, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA. 2014;111(13):4970–5.
CAS
PubMed
PubMed Central
Google Scholar
Munster VJ, de Wit E, Feldmann H. Pneumonia from human coronavirus in a macaque model. N Engl J Med. 2013;368(16):1560–2.
CAS
PubMed
Google Scholar
de Wit E, Rasmussen AL, Falzarano D, Bushmaker T, Feldmann F, Brining DL. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci USA. 2013;110:16598–603.
PubMed
PubMed Central
Google Scholar
Falzarano D, et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog. 2014;10(8):e1004250.
PubMed
PubMed Central
Google Scholar
Chan JF-W, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212(12):1904–13.
CAS
PubMed
Google Scholar
McAuliffe J, et al. Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology. 2004;330(1):8–15.
CAS
PubMed
Google Scholar
Lawler JV, et al. Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med. 2006;3(5):e149–e149149.
PubMed
PubMed Central
Google Scholar
Jiang S, He Y, Liu S. SARS vaccine development. Emerg Infect Dis J. 2005;11(7):1016.
CAS
Google Scholar
Du L, Tai W, Zhou Y, Jiang S. Vaccines for the prevention against the threat of MERS-CoV. Expert Rev Vaccines. 2016;15(9):1123–34.
CAS
PubMed
PubMed Central
Google Scholar
Payne S. Chapter 6—immunity and resistance to viruses. In: Payne SBT-V, editor. Viruses From Understanding to Investigation. Academic Press; 2017. p. 61–71.
Haagmans BL, et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science. 2016;351(6268):77–81.
CAS
PubMed
Google Scholar
Pascal KE, et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci USA. 2015;112(28):8738–43.
CAS
PubMed
PubMed Central
Google Scholar
Liu WJ, et al. Protective T cell responses featured by concordant recognition of Middle East respiratory syndrome coronavirus-derived CD8+ T cell epitopes and host MHC. J Immunol. 2017;198(2):873–82.
CAS
PubMed
Google Scholar
Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol. 2010;84(18):9318–25.
CAS
PubMed
PubMed Central
Google Scholar
Li T, et al. Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus. PLoS One. 2006;1(1):e24–e2424.
PubMed
PubMed Central
Google Scholar
Park WB, Perera RAPM, Choe PG, Lau EHY, Choi SJ, Chun JY. Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea. Emerg Infect Dis. 2015;21:2186–9.
CAS
PubMed
PubMed Central
Google Scholar
Min C-K, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep. 2016;6(1):25359.
CAS
PubMed
PubMed Central
Google Scholar
Gu J, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202(3):415–24.
CAS
PubMed
PubMed Central
Google Scholar
Zhao J, et al. Recovery from the Middle East respiratory syndrome is associated with antibody and T cell responses. Sci Immunol. 2017;2(14):eaan5393.
PubMed
PubMed Central
Google Scholar
Tang F, et al. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a 6-year follow-up study. J Immunol. 2011;186(12):7264–8.
CAS
PubMed
Google Scholar
Liu W, et al. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis. 2006;193(6):792–5.
PubMed
Google Scholar
Payne DC, et al. Persistence of antibodies against Middle East respiratory syndrome coronavirus. Emerg Infect Dis. 2016;22(10):1824–6.
PubMed
PubMed Central
Google Scholar
Bradburne AF, Somerset BA. Coronative antibody tires in sera of healthy adults and experimentally infected volunteers. J Hyg (Lond). 1972;70(2):235–44.
CAS
Google Scholar
Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990;105(2):435–46.
CAS
PubMed
PubMed Central
Google Scholar
Dimmock K, Easton NJ, Leppard AJ. Introduction to modern virology. In: Malden MA, editor. Introduction to modern virology. New York: Blackwell Pub; 2007. p. 65.
Google Scholar
Vennema H, et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol. 1990;64(3):1407–9.
CAS
PubMed
PubMed Central
Google Scholar
Houser KV, et al. Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody. PLoS Pathog. 2017;13(8):e1006565–e10065651006565.
PubMed
PubMed Central
Google Scholar
Greenough TC, et al. Development and characterization of a severe acute respiratory syndrome—associated coronavirus—neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis. 2005;191(4):507–14.
CAS
PubMed
Google Scholar
Subbarao K, et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol. 2004;78(7):3572–7.
CAS
PubMed
PubMed Central
Google Scholar
Hearnden C, Lavelle EC. Chapter 21—adjuvant strategies for vaccines: the use of adjuvants within the cancer vaccine setting. In: Prendergast GC, Jaffee E, editors. EMBT-CI. San Diego: Academic Press; 2013. p. 333–349.
Honda-Okubo Y, Barnard D, Ong CH, Peng B-H, Tseng C-TK, Petrovsky N. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol. 2015;89(6):2995–3007.
CAS
PubMed
Google Scholar
Blaauboer SM, Mansouri S, Tucker HR, Wang HL, Gabrielle VD, Jin L. The mucosal adjuvant cyclic di-GMP enhances antigen uptake and selectively activates pinocytosis-efficient cells in vivo. Elife. 2015;4:e06670.
PubMed Central
Google Scholar
N.-N. Releases. NIH clinical trial of investigational vaccine for COVID-19 begins. 2020. [Online]. https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins. Accessed 10 Apr 2020.
Hodgson J. The pandemic pipeline. Nat Biotechnol. 2020. Online ahead of print.
Agnihothram S, et al. Evaluation of serologic and antigenic relationships between Middle Eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J Infect Dis. 2013;209(7):995–1006.
PubMed
Google Scholar
Peng H, et al. Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients. Virology. 2006;351(2):466–75.
CAS
PubMed
Google Scholar